Skip to main content

Peer Review reports

From: Safety and tolerability study of sotrovimab (VIR-7831) prophylaxis against COVID-19 infection in immunocompromised individuals with impaired SARS-CoV-2 humoral immunity

Original Submission
4 Jul 2022 Submitted Original manuscript
13 Aug 2022 Reviewed Reviewer Report - Masoume Mansouri
29 Jan 2023 Reviewed Reviewer Report - Mary-Theresa Usuanlele
1 Mar 2023 Author responded Author comments - Isabel Helena Gonzalez-Bocco
Resubmission - Version 2
1 Mar 2023 Submitted Manuscript version 2
2 May 2023 Author responded Author comments - Isabel Helena Gonzalez-Bocco
Resubmission - Version 3
2 May 2023 Submitted Manuscript version 3
Publishing
26 May 2023 Editorially accepted
16 Jun 2023 Article published 10.1186/s40814-023-01325-y

You can find further information about peer review here.

Back to article page